ZGNX News and Press, Zogenix Inc. From 11/04/21

Zogenix (NASDAQ:ZGNX): Q3 GAAP EPS of $1.04 beats by $2.02. Revenue of $22.6M (+690.2% Y/Y) misses by $0.11M. Press Release For further details see: Zogenix EPS beats by $2.02, misses on revenue

FINTEPLA ® net product sales of $21.4 million and total revenue of $22.6 million in the third quarter, representing quarter-over-quarter increases of 22% and 20%, respectively Submitted supplemental New Drug Application (sNDA) to the U.S. Food and Drug Adminis...

EMERYVILLE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will host a key opinion leader (KOL) webinar on thymidine kinase 2 deficiency (TK2d) and MT-1621 on Monday, November 8,...

EMERYVILLE, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update confe...

Today, we revisit biopharma name Zogenix, Inc. for the first time since early this year. Its recently approved compound FINTEPLA continues to ramp up sales and some new approved indications may be on the horizon in the near future. A full investment analysis is presented in the pa...

Median reduction in drop seizure frequency was 39.4% at 3 months (n= 227; p<0.0001) and 51.8% for patients assessed over months 10 to 12 (n=170; p<0.0001). A Supplemental New Drug Application (sNDA) was recently submitted seeking FDA approval for the use of FINTEPLA in LGS...

Supplemental New Drug Application (sNDA) submission is supported by existing clinical data, including positive data from Company’s Phase 3 trial, Study 1601, in which the primary endpoint was met with high statistical significance. Lennox-Gastaut Syndrome (LGS) is estimated t...

Zogenix plans to submit a new drug application (J-NDA) for FINTEPLA in Japan for the treatment of seizures associated with Dravet syndrome by year end. Dravet syndrome is a rare, life-long form of epilepsy marked by severe seizures, significant developmental delays, frequent hos...

EMERYVILLE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen new employees. The awards were made on August 15, 2021, under Zogenixȁ...

Zogenix, Inc. (ZGNX) Q2 2021 Results Conference Call August 05, 2021 04:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Dr. Stephen Farr - CEO Ashish Sagrolikar - Chief Commercial Officer Michael Smith - CFO Conference Call Participants Paul Matteis - Stifel Marc Goodman - SVB ...